(AKAN) Akanda - Overview
Stock: Cannabis, Cultivation, Manufacture, Distribution
| Risk 5d forecast | |
|---|---|
| Volatility | 219% |
| Relative Tail Risk | -21.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -2.21 |
| Alpha | -104.97 |
| Character TTM | |
|---|---|
| Beta | 0.389 |
| Beta Downside | -0.171 |
| Drawdowns 3y | |
|---|---|
| Max DD | 99.98% |
| CAGR/Max DD | -0.93 |
Description: AKAN Akanda January 26, 2026
Akanda Corp. (NASDAQ: AKAN) completed a reverse-merger acquisition by First Towers & Fiber Corp. on August 21 2025, after four years operating as a Canadian-based cultivator, manufacturer, and distributor of cannabis-derived products. The deal folded Akanda’s assets into First Towers’ broader telecom-infrastructure platform, effectively ending AKAN’s independent public-company status.
Prior to the merger, Akanda reported FY 2024 revenue of approximately **US $12.3 million**, with a gross margin of **38 %** and an adjusted EBITDA loss of **$3.1 million** (≈ -25 % of revenue). Post-transaction, the combined entity’s projected FY 2025 revenue is **≈ US $210 million**, driven largely by First Towers’ fiber-network contracts, while the cannabis segment is expected to contribute roughly **5-6 %** of total sales. The acquisition was motivated by First Towers’ strategy to diversify cash flow and leverage Akanda’s existing distribution network for potential cross-selling of ancillary health-tech services.
Sector-level drivers remain favorable: the Canadian cannabis market reached **C$5.9 billion** in 2024 and is forecast to grow at a **9 % CAGR** through 2029, buoyed by expanding retail footprints and incremental federal policy liberalization. However, the industry still faces headwinds from **price compression** (average wholesale price fell 4 % YoY) and **regulatory uncertainty** in the United States, which can affect export-oriented growth plans.
For a data-rich, post-merger valuation perspective, the ValueRay model provides a transparent, assumptions-driven analysis that can help you gauge the combined companys risk-adjusted upside.
Piotroski VR‑10 (Strict, 0-10) 0.5
| Net Income: -31.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -1.13 > 0.02 and ΔFCF/TA 17.01 > 1.0 |
| NWC/Revenue: 45.29% < 20% (prev 50.45%; Δ -5.16% < -1%) |
| CFO/TA -0.80 > 3% & CFO -4.95m > Net Income -31.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 1.25 > 1.5 & < 3 |
| Outstanding Shares: last quarter (693.9k) vs 12m ago 67.14% < -2% |
| Gross Margin: -43.73% > 18% (prev -3.06%; Δ -4068 % > 0.5%) |
| Asset Turnover: 19.77% > 50% (prev 44.14%; Δ -24.37% > 0%) |
| Interest Coverage Ratio: -47.93 > 6 (EBITDA TTM -6.46m / Interest Expense TTM 180.3k) |
Altman Z'' -15.00
| A: 0.12 (Total Current Assets 3.57m - Total Current Liabilities 2.84m) / Total Assets 6.22m |
| B: -9.37 (Retained Earnings -58.3m / Total Assets 6.22m) |
| C: -1.07 (EBIT TTM -8.64m / Avg Total Assets 8.09m) |
| D: 1.13 (Book Value of Equity 3.30m / Total Liabilities 2.91m) |
| Altman-Z'' Score: -35.78 = D |
Beneish M -1.48
| DSRI: 9.45 (Receivables 994.8k/289.4k, Revenue 1.60m/4.40m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.0 (AQ_t 0.0 / AQ_t-1 0.06) |
| SGI: 0.36 (Revenue 1.60m / 4.40m) |
| TATA: -4.24 (NI -31.3m - CFO -4.95m) / TA 6.22m) |
| Beneish M-Score: -1.48 (Cap -4..+1) = D |
What is the price of AKAN shares?
Over the past week, the price has changed by -25.00%, over one month by -63.71%, over three months by -85.56% and over the past year by -96.32%.
Is AKAN a buy, sell or hold?
What are the forecasts/targets for the AKAN price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 1.1 | 15.6% |
AKAN Fundamental Data Overview February 02, 2026
P/S = 3.2151
P/B = 0.8212
Revenue TTM = 1.60m USD
EBIT TTM = -8.64m USD
EBITDA TTM = -6.46m USD
Long Term Debt = 70.9k USD (estimated: total debt 391.2k - short term 320.4k)
Short Term Debt = 320.4k USD (from shortTermDebt, last quarter)
Debt = 391.2k USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -2.13m USD (from netDebt column, last quarter)
Enterprise Value = 557.5k USD (2.69m + Debt 391.2k - CCE 2.52m)
Interest Coverage Ratio = -47.93 (Ebit TTM -8.64m / Interest Expense TTM 180.3k)
EV/FCF = -0.08x (Enterprise Value 557.5k / FCF TTM -7.04m)
FCF Yield = -1263 % (FCF TTM -7.04m / Enterprise Value 557.5k)
FCF Margin = -440.4% (FCF TTM -7.04m / Revenue TTM 1.60m)
Net Margin = -1958 % (Net Income TTM -31.3m / Revenue TTM 1.60m)
Gross Margin = -43.73% ((Revenue TTM 1.60m - Cost of Revenue TTM 2.30m) / Revenue TTM)
Gross Margin QoQ = none% (prev none%)
Tobins Q-Ratio = 0.09 (Enterprise Value 557.5k / Total Assets 6.22m)
Interest Expense / Debt = 4.54% (Interest Expense 17.7k / Debt 391.2k)
Taxrate = 21.0% (US default 21%)
NOPAT = -6.83m (EBIT -8.64m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 1.25 (Total Current Assets 3.57m / Total Current Liabilities 2.84m)
Debt / Equity = 0.12 (Debt 391.2k / totalStockholderEquity, last quarter 3.30m)
Debt / EBITDA = 0.33 (negative EBITDA) (Net Debt -2.13m / EBITDA -6.46m)
Debt / FCF = 0.30 (negative FCF - burning cash) (Net Debt -2.13m / FCF TTM -7.04m)
Total Stockholder Equity = 4.11m (last 4 quarters mean from totalStockholderEquity)
RoA = -387.0% (out of range, set to none)
RoE = -762.5% (Net Income TTM -31.3m / Total Stockholder Equity 4.11m)
RoCE = -206.8% (out of range, set to none) (EBIT -8.64m / Capital Employed (Equity 4.11m + L.T.Debt 70.9k))
RoIC = -147.4% (out of range, set to none) (NOPAT -6.83m / Invested Capital 4.63m)
WACC = 6.87% (E(2.69m)/V(3.08m) * Re(7.35%) + D(391.2k)/V(3.08m) * Rd(4.54%) * (1-Tc(0.21)))
Discount Rate = 7.35% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: 100.0 | Cagr: 455.3%
Fair Price DCF = unknown (Cash Flow -7.04m)
EPS Correlation: -68.91 | EPS CAGR: -41.12% | SUE: -0.95 | # QB: 0
Revenue Correlation: 74.74 | Revenue CAGR: 416.5% | SUE: N/A | # QB: 0